CN102597269A - 用于鉴定患者是否将是免疫治疗的反应者的方法 - Google Patents

用于鉴定患者是否将是免疫治疗的反应者的方法 Download PDF

Info

Publication number
CN102597269A
CN102597269A CN2010800494497A CN201080049449A CN102597269A CN 102597269 A CN102597269 A CN 102597269A CN 2010800494497 A CN2010800494497 A CN 2010800494497A CN 201080049449 A CN201080049449 A CN 201080049449A CN 102597269 A CN102597269 A CN 102597269A
Authority
CN
China
Prior art keywords
genes
gene
patient
labeled
another aspect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800494497A
Other languages
English (en)
Chinese (zh)
Inventor
V·布里查德
B·G·E·L·G·迪奇尔
O·格鲁塞勒
J·罗亚赫德
F·乌罗亚-蒙托亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN102597269A publication Critical patent/CN102597269A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN2010800494497A 2009-09-18 2010-09-17 用于鉴定患者是否将是免疫治疗的反应者的方法 Pending CN102597269A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US27704609P 2009-09-18 2009-09-18
US61/277046 2009-09-18
US27838709P 2009-10-06 2009-10-06
GBGB0917457.4A GB0917457D0 (en) 2009-10-06 2009-10-06 Method
GB0917457.4 2009-10-06
US61/278387 2009-10-06
PCT/EP2010/063751 WO2011033095A1 (en) 2009-09-18 2010-09-17 Method for identifying whether a patient will be responder or not to immunotherapy

Publications (1)

Publication Number Publication Date
CN102597269A true CN102597269A (zh) 2012-07-18

Family

ID=41393894

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800494497A Pending CN102597269A (zh) 2009-09-18 2010-09-17 用于鉴定患者是否将是免疫治疗的反应者的方法

Country Status (14)

Country Link
US (1) US20110070268A1 (enExample)
EP (1) EP2478116A1 (enExample)
JP (1) JP2013505008A (enExample)
KR (1) KR20130055553A (enExample)
CN (1) CN102597269A (enExample)
AU (1) AU2010297248A1 (enExample)
BR (1) BR112012006088A2 (enExample)
CA (1) CA2773666A1 (enExample)
EA (1) EA201290107A1 (enExample)
GB (1) GB0917457D0 (enExample)
IL (1) IL218313A0 (enExample)
MX (1) MX2012003329A (enExample)
SG (1) SG179129A1 (enExample)
WO (1) WO2011033095A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109416925A (zh) * 2016-05-05 2019-03-01 南托米克斯有限责任公司 检查点失效和使检查点失效的方法
CN115495026A (zh) * 2022-11-21 2022-12-20 杭州字节方舟科技有限公司 一种优化内存处理方法、装置、设备及存储介质

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906523A1 (en) * 2013-03-15 2014-09-25 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
ES2946681T3 (es) 2014-07-02 2023-07-24 Myriad Mypath Llc Genes y firmas génicas para el diagnóstico y tratamiento del melanoma
WO2016109546A2 (en) * 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
KR102169901B1 (ko) * 2019-05-17 2020-10-26 연세대학교 산학협력단 Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
IL296568A (en) * 2020-03-17 2022-11-01 Regeneron Pharma Methods and systems for determining responders to treatment
EP4161658A4 (en) * 2020-06-01 2024-10-02 Dana-Farber Cancer Institute, Inc. Methods for modulating mhc-i expression and immunotherapy uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140958A2 (en) * 2006-06-02 2007-12-13 Glaxosmithkline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
CA2319309C (en) 1998-02-05 2010-08-10 Smithkline Beecham Biologicals S.A. Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
DE69929444T2 (de) 1998-08-10 2006-09-28 Antigenics Inc., Woburn Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
CA2361009C (en) 1999-01-29 2012-10-23 Corixa Corporation Her-2/neu fusion proteins
CN100430478C (zh) 1999-03-11 2008-11-05 史密丝克莱恩比彻姆生物有限公司 Casb618多核苷酸和多肽及其用途
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
PL209127B1 (pl) 2000-02-23 2011-07-29 Smithkline Beecham Biolog Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka
US20020076469A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
DE10127572A1 (de) * 2001-05-30 2002-12-05 Pathoarray Gmbh Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
WO2003050257A2 (en) * 2001-12-06 2003-06-19 University Of Florida Targeting leukemia cells
EP1482795B1 (en) 2002-02-04 2009-11-11 Corixa Corporation New immunoeffector compounds
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
MXPA04012443A (es) 2002-06-11 2005-04-19 Glaxosmithkline Biolog Sa Composiciones inmunogenicas.
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004076565A2 (en) * 2003-02-25 2004-09-10 Technical Knockout, Inc. Improved coated weight plates, dumbbells and method of manufacture
EP1605811A4 (en) * 2003-02-28 2008-06-11 Bayer Pharmaceuticals Corp EXPRESSION PROFILES FOR BREAST CANCER AND METHODS OF USE
US20050095607A1 (en) * 2003-03-07 2005-05-05 Arcturus Bioscience, Inc. University Of Louisville Breast cancer signatures
EP1608964A4 (en) 2003-03-14 2009-07-15 Peter Maccallum Cancer Inst CREATING AN EXPRESSION PROFILE OF TUMORS
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
US7598287B2 (en) * 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
JP2007507222A (ja) * 2003-05-28 2007-03-29 ゲノミック ヘルス， インコーポレイテッド 化学療法に対する応答を予測するための遺伝子発現マーカー
EP2348110B1 (en) 2003-05-30 2013-03-27 OncoTherapy Science, Inc. Process for screening a drug response in cancer patients
EP1651775A2 (en) * 2003-06-18 2006-05-03 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
EP1980629A3 (en) * 2003-08-28 2008-12-17 Ipsogen Identification of an erbb2 gene expression signature in breast cancers
WO2005032495A2 (en) * 2003-10-03 2005-04-14 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
US20070110710A1 (en) * 2003-11-05 2007-05-17 New England Medical Center Hospitals, Inc. Treatment with immunoregulatory t cells
WO2005075680A1 (ja) * 2004-02-09 2005-08-18 Fuso Pharmaceutical Industries, Ltd. 核酸検出方法およびその利用
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
US20070237717A1 (en) * 2004-04-05 2007-10-11 Roland Martin Methods for Selection of Subjects for Multiple Sclerosis Therapy
US7332281B2 (en) * 2004-04-27 2008-02-19 Sagres Discovery, Inc. Therapeutic targets in cancer
WO2006054129A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
BRPI0518734A2 (pt) 2004-11-30 2008-12-02 Veridex Llc prognàstico de cÂncer de pulmço
US20070059720A9 (en) * 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
US7666595B2 (en) 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
GB0504302D0 (en) 2005-03-02 2005-04-06 Univ Dublin Markers for melanoma
EP1863930A2 (en) 2005-04-01 2007-12-12 NCC Technology Ventures Pte Limited Materials and methods relating to breast cancer classification
WO2006124836A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
US20070111257A1 (en) * 2005-07-07 2007-05-17 Kohne David E Improved protein expression comparison assay results and applications
JP5171812B2 (ja) * 2006-04-27 2013-03-27 ユニベルシテ ドゥ モントリオール 移植片対宿主病のリスクの評価および低減
WO2009034055A1 (en) * 2007-09-10 2009-03-19 Novartis Forschungsstiftung, Zweigniederlassung Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy
WO2009068621A1 (en) * 2007-11-30 2009-06-04 Glaxosmithkline Biologicals S.A. Method for classifying cancer patients as responder or non-responder to immunotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140958A2 (en) * 2006-06-02 2007-12-13 Glaxosmithkline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BONOME T 等: "Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary", 《CANCER RES》, vol. 65, 31 December 2005 (2005-12-31), pages 10602 - 10612, XP002511194, DOI: doi:10.1158/0008-5472.CAN-05-2240 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109416925A (zh) * 2016-05-05 2019-03-01 南托米克斯有限责任公司 检查点失效和使检查点失效的方法
CN115495026A (zh) * 2022-11-21 2022-12-20 杭州字节方舟科技有限公司 一种优化内存处理方法、装置、设备及存储介质
CN115495026B (zh) * 2022-11-21 2023-03-10 杭州字节方舟科技有限公司 一种优化内存处理方法、装置、设备及存储介质

Also Published As

Publication number Publication date
EA201290107A1 (ru) 2012-10-30
JP2013505008A (ja) 2013-02-14
AU2010297248A1 (en) 2012-04-12
KR20130055553A (ko) 2013-05-28
MX2012003329A (es) 2012-04-20
US20110070268A1 (en) 2011-03-24
BR112012006088A2 (pt) 2020-08-11
IL218313A0 (en) 2012-04-30
CA2773666A1 (en) 2011-03-24
GB0917457D0 (en) 2009-11-18
WO2011033095A1 (en) 2011-03-24
EP2478116A1 (en) 2012-07-25
SG179129A1 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
BRPI0712497A2 (pt) perfil de gene, uso de um perfil, método para identificar um perfil, usos de uma sonda e de um kit de microarranjo para a identificação da expressão diferencial de pelo menos um produto de gene de ativação imune, microarranjo, kit de diagnóstico, e, método para tratar um paciente, e para induzir um perfil de gene respondedor em paciente distinguido como um não respondedor.
CN102597269A (zh) 用于鉴定患者是否将是免疫治疗的反应者的方法
US20100247580A1 (en) Method for Classifying Cancer Patients as Responder or Non-Responder to Immunotherapy
CN101932723B (zh) 改进的对mage-a表达的检测
JP6901505B2 (ja) 全細胞がんワクチンおよびその選択のための方法
US20090215709A1 (en) Methylation markers for diagnosis and treatment of cancers
US20190048422A1 (en) Compositions and methods for detecting and diagnosing neoplasia
CN102575284A (zh) 改进的基因表达检测
US20100216131A1 (en) Gene expression profiling of esophageal carcinomas
JP2009539404A (ja) 大腸癌の早期検出および予後のためのメチル化マーカー
WO2015184061A2 (en) Activating jak kinase biomarkers predictive of anti-immune checkpoint inhibitor response
CN101351563A (zh) 用于预测或监测病人对于ErbB受体药物的响应的方法
Luoh Amplification and expression of genes from the 17q11∼ q12 amplicon in breast cancer cells
JP2014527411A (ja) 癌におけるｐｒａｍｅ遺伝子発現の検出
JP5705191B2 (ja) Ｍａｇｅ−ａ３マーカーの特異的検出のためのプライマーおよびプローブを含む癌の検出および診断の方法
US20100166783A1 (en) Method
Cobarrubias et al. Preliminary identification of Human Leukocyte Antigen (HLA) CLASS II DRB1 Allelic variants in selected Filipino cancer patient samples
CA2646194A1 (en) Cancer detection reagents and uses in pathology and diagnostics and cancer cell death
Wu et al. Exploration of Specific Population for Adjuvant Capecitabine Escalation Therapy in Early-Stage Triple-Negative Breast Cancer: A Retrospective Biological Sample Analysis of the CBCSG010 Clinical Trial

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120718